A Study of SI-6603 in Patients With Lumbar Disc Herniation

March 21, 2023 updated by: Seikagaku Corporation
The purpose of this study is to evaluate the efficacy and safety of SI-6603 (condoliase) in patients with lumbar disc herniation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

385

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States
    • California
      • Gold River, California, United States
      • Laguna Hills, California, United States
      • Los Gatos, California, United States
      • Murrieta, California, United States
      • Riverside, California, United States
    • Colorado
      • Denver, Colorado, United States
    • Florida
      • Hialeah, Florida, United States
      • Jacksonville, Florida, United States
      • Merritt Island, Florida, United States
      • Miami, Florida, United States
      • Naples, Florida, United States
      • North Miami Beach, Florida, United States
      • Orlando, Florida, United States
      • Pinellas Park, Florida, United States
      • Saint Petersburg, Florida, United States
      • Sarasota, Florida, United States
      • Sunrise, Florida, United States
      • Winter Park, Florida, United States
    • Georgia
      • Marietta, Georgia, United States
      • Newnan, Georgia, United States
    • Illinois
      • Bloomington, Illinois, United States
    • Indiana
      • Carmel, Indiana, United States
    • Louisiana
      • Shreveport, Louisiana, United States
    • Missouri
      • Saint Peters, Missouri, United States
    • New York
      • Hartsdale, New York, United States
    • Oregon
      • Eugene, Oregon, United States
    • Pennsylvania
      • State College, Pennsylvania, United States
    • South Carolina
      • Charleston, South Carolina, United States
    • Texas
      • Dallas, Texas, United States
    • Utah
      • Sandy, Utah, United States
    • Washington
      • Edmonds, Washington, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with lumbar disc herniation (L4-L5 or L5-S1) as assessed by MRI and clinical symptoms corresponding to position of the impaired nerve root.
  • Patients assessed as positive in the SLR test.
  • Patients with sciatica in either leg.
  • Patients with no improvement from conservative treatment

Exclusion Criteria:

  • Patients who have 2 or more lumbar disc herniations as assessed by MRI.
  • Patients in whom a rupture into the posterior longitudinal ligament is identified by MRI.
  • Patients who have received spinal injection, epidural injection, nerve block within 3 weeks prior to the time of informed consent.
  • Patients who have undergone lumbar operation, or lumbar percutaneous nucleotomy or lumbar intradiscal therapies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SI-6603
SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
Drug: Condoliase
1.25U, intradiscal injection, one time
Sham Comparator: Control
Sham injection
Drug: placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Leg pain
Time Frame: 13 weeks
Assessed by Visual Analog Scale (VAS)
13 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Responder rate evaluation
Time Frame: 13 weeks
Assessed by leg pain (VAS), Oswestry Disability Index disability questionnaire, neurologic status (motor, sensory, reflexes), and no treatment failure
13 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seikagaku Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (Actual)

November 1, 2015

Study Completion (Actual)

August 1, 2017

Study Registration Dates

First Submitted

September 4, 2013

First Submitted That Met QC Criteria

September 12, 2013

First Posted (Estimate)

September 13, 2013

Study Record Updates

Last Update Posted (Actual)

March 23, 2023

Last Update Submitted That Met QC Criteria

March 21, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 6603/1131

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Disc Disease

Clinical Trials on placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe